Transformative Therapies For Retinal Diseases


Our Pipeline

Learn More

CLINICAL TRIALS

Learn More

NEWS

Learn More

Our Story

Iveric Bio, An Astellas Company, is an innovative biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with significant unmet medical needs.

Who We Are


An experienced, passionate team with a proven track record in collaborative clinical development and commercialization of novel therapies. Our team is focused on delivering strategic solutions that better the lives of patients, eyecare professionals, and more. With expertise in ophthalmology and retinal diseases, we welcome the challenges of the future.

Read More

What We're Doing


Our strategy is focused on developing multiple, complementary assets to treat a broad spectrum of retinal diseases. We intend to do this by studying avacincaptad pegol in autosomal recessive stargardt disease and by advancing the development of IC-500 our HtrA1 inhibitor. Having both avacincaptad pegol and IC-500 in our pipeline positions us to potentially provide treatments for patients with various types and stages of AMD, the leading cause of vision loss in the elderly. We are also developing novel gene therapy technology to treat orphan inherited retinal diseases (IRDs). IRDs can be caused by many different mutations of a single gene. Our strategy is to develop mutation independent treatment options to potentially treat the entire group of patients with
a particular IRD.

Read More

Information for Patients
If you have been recently diagnosed with a retinal condition by your eye care professional, please visit the link below.
Learn More